Supplier of assay kits, antibodies, biochemicals, and proteins and provider of contract research services
A physician should determine your dose
RGN-352 was shown to be safe and well-tolerated with no serious drug-related adverse events reported (PMID: 20536472) Phase 2 AMI trial (incomplete): RegeneRx designed a Phase 2 proof-of-concept trial (NCT01311518) to evaluate RGN-352 in approximately 75 patients with acute ST-segment elevation myocardial infarction (heart attack)
Research Applications In controlled research environments, the BPC-157 / TB-500 blend may be utilised in experimental models designed to explore peptide signalling systems and intracellular regulatory pathways
The most frequently encountered are 5 mg, 10 mg, 15 mg, and 30 mg vials
Beta-3 adrenergic receptors, the primary target of AOD-9604, are highly expressed in white and brown adipose tissue but have minimal presence in appetite-regulating brain regions